Is Organigram Global Inc. (NASDAQ:OGI) a buy in 2026?
Hold. Organigram Global Inc. is a wait-and-watch at today's price, not a fresh buy.
Cannabis survivor with cash, brands and a US option, but Canadian price wars cap the upside until rescheduling actually happens.
Where OGI is headed
By mid-2028, Organigram is one of maybe four Canadian cannabis producers still standing with positive free cash flow, a real brand portfolio, and a balance sheet that didn't get vaporized by the 2022-2025 price war. The SHRED franchise holds its #1 flower position in Canada, the Edison JOLTS pastille format has become the template the rest of the market copies, and the company is generating $30-40M of annual free cash flow on roughly C$220M of revenue. That's not a growth story. That's a survival-into-consolidation story, and at a $136M market cap, you're paying about 4x forward FCF for it.
Read the full Compass Direction on OGI
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $1.07).
See the full OGI analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Organigram Global Inc. (NASDAQ:OGI) a buy in 2026?
Hold. Organigram Global Inc. is a wait-and-watch at today's price, not a fresh buy. Cannabis survivor with cash, brands and a US option, but Canadian price wars cap the upside until rescheduling actually happens.
What is OGI's Compass Score?
Organigram Global Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for OGI?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the OGI page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.